High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer

Abstract 27-hydroxycholesterol (27HC), synthesized from cholesterol by the enzyme CYP27A1, differentially impacts estrogen receptor positive (ER+) breast cancer (BC) cell growth depending on estrogen levels. This study examined the association between CYP27A1 expression and prognosis in a cohort of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Inasu, Pär-Ola Bendahl, Mårten Fernö, Per Malmström, Signe Borgquist, Siker Kimbung
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/42ce64d0f0ad4806b4fab2233af6540e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:42ce64d0f0ad4806b4fab2233af6540e
record_format	dspace
spelling	oai:doaj.org-article:42ce64d0f0ad4806b4fab2233af6540e2021-12-02T15:15:23ZHigh CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer10.1038/s41523-021-00333-62374-4677https://doaj.org/article/42ce64d0f0ad4806b4fab2233af6540e2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00333-6https://doaj.org/toc/2374-4677Abstract 27-hydroxycholesterol (27HC), synthesized from cholesterol by the enzyme CYP27A1, differentially impacts estrogen receptor positive (ER+) breast cancer (BC) cell growth depending on estrogen levels. This study examined the association between CYP27A1 expression and prognosis in a cohort of 193 premenopausal patients with lymph node-negative primary BC with limited exposure to adjuvant systemic cancer treatments. In multivariable analyses among patients with ER+ tumors, high CYP27A1 protein and mRNA expressions were associated with four- and eight-fold reductions in the incidence of distant recurrence-free survival events: HRadj = 0.26, 95% CI = 0.07–0.93 and HRadj = 0.13, 95% CI = 0.03–0.60, respectively. In vitro studies revealed that 27HC treatment potently inhibited ER+ BC cell proliferation under lipid-depleted conditions regardless of estradiol levels, transcriptionally mediated through the downregulation of ER signaling with a concomitant upregulation of cholesterol export. Importantly, if validated, these results may have implications for adjuvant treatment decisions in premenopausal patients, especially when de-escalation of therapy is being considered.Maria InasuPär-Ola BendahlMårten FernöPer MalmströmSigne BorgquistSiker KimbungNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maria Inasu Pär-Ola Bendahl Mårten Fernö Per Malmström Signe Borgquist Siker Kimbung High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
description	Abstract 27-hydroxycholesterol (27HC), synthesized from cholesterol by the enzyme CYP27A1, differentially impacts estrogen receptor positive (ER+) breast cancer (BC) cell growth depending on estrogen levels. This study examined the association between CYP27A1 expression and prognosis in a cohort of 193 premenopausal patients with lymph node-negative primary BC with limited exposure to adjuvant systemic cancer treatments. In multivariable analyses among patients with ER+ tumors, high CYP27A1 protein and mRNA expressions were associated with four- and eight-fold reductions in the incidence of distant recurrence-free survival events: HRadj = 0.26, 95% CI = 0.07–0.93 and HRadj = 0.13, 95% CI = 0.03–0.60, respectively. In vitro studies revealed that 27HC treatment potently inhibited ER+ BC cell proliferation under lipid-depleted conditions regardless of estradiol levels, transcriptionally mediated through the downregulation of ER signaling with a concomitant upregulation of cholesterol export. Importantly, if validated, these results may have implications for adjuvant treatment decisions in premenopausal patients, especially when de-escalation of therapy is being considered.
format	article
author	Maria Inasu Pär-Ola Bendahl Mårten Fernö Per Malmström Signe Borgquist Siker Kimbung
author_facet	Maria Inasu Pär-Ola Bendahl Mårten Fernö Per Malmström Signe Borgquist Siker Kimbung
author_sort	Maria Inasu
title	High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
title_short	High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
title_full	High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
title_fullStr	High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
title_full_unstemmed	High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
title_sort	high cyp27a1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/42ce64d0f0ad4806b4fab2233af6540e
work_keys_str_mv	AT mariainasu highcyp27a1expressionisabiomarkeroffavorableprognosisinpremenopausalpatientswithestrogenreceptorpositiveprimarybreastcancer AT parolabendahl highcyp27a1expressionisabiomarkeroffavorableprognosisinpremenopausalpatientswithestrogenreceptorpositiveprimarybreastcancer AT martenferno highcyp27a1expressionisabiomarkeroffavorableprognosisinpremenopausalpatientswithestrogenreceptorpositiveprimarybreastcancer AT permalmstrom highcyp27a1expressionisabiomarkeroffavorableprognosisinpremenopausalpatientswithestrogenreceptorpositiveprimarybreastcancer AT signeborgquist highcyp27a1expressionisabiomarkeroffavorableprognosisinpremenopausalpatientswithestrogenreceptorpositiveprimarybreastcancer AT sikerkimbung highcyp27a1expressionisabiomarkeroffavorableprognosisinpremenopausalpatientswithestrogenreceptorpositiveprimarybreastcancer
_version_	1718387502567391232

High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer

Ejemplares similares